New timing for lung cancer combo shows promise in early trial
NCT ID NCT04163432
First seen Dec 18, 2025 · Last updated Jun 13, 2026 · Updated 25 times
Summary
This study tests two different timing schedules of a drug combination (durvalumab, pemetrexed, and carboplatin) in adults with advanced non-squamous non-small cell lung cancer. The goal is to see if staggering the doses improves how long the cancer is controlled. 43 participants were enrolled, and researchers measured tumor shrinkage or stability using standard criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.